Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.
about
Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignNeutralizing antibody response to hepatitis C virusToward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing AntibodyStructural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization EscapeAn alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateUnexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designA Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal AntibodiesBroadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceA Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.Structural basis for broad neutralization of hepatitis C virus quasispecies.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 culturesNaturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.TNF-α Induced by Hepatitis C Virus via TLR7 and TLR8 in Hepatocytes Supports Interferon Signaling via an Autocrine Mechanism.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoproteinCharacterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entryHepatitis C Virus Resistance to Carbohydrate-Binding AgentsBroad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionImmunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.CD81 and hepatitis C virus (HCV) infection.Hepatitis C virus evasion mechanisms from neutralizing antibodiesStructural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.Viral evasion and challenges of hepatitis C virus vaccine development.Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.Unexpected maintenance of hepatitis C viral diversity following liver transplantation.The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.
P2860
Q26783378-F034B85E-2AB8-4C3B-ABB3-6146CD6657FCQ26801759-E4D3D820-F92C-4ED4-A072-91B3D957F8C2Q27027484-4CA3666D-2FBE-40C9-B4F0-FB8030AE9F6AQ27673453-7D39AC5A-88EA-4E4F-90EF-70995A8BB9D4Q27678252-1F76BC74-CB36-41B4-BF18-08F815C2F4B9Q27684354-64F6BC63-E28F-4BF9-A303-8E8BEF971A0FQ28482261-52AC3322-6FD1-48C2-B0D9-D1D5387E0E02Q30364309-6627EA89-455E-4D10-8DB2-55305EFD9379Q30374314-C7CB6F42-1D76-46BE-987C-D3E4FD843796Q30383939-4F5B0A82-2B32-463B-870A-3B78B20B6827Q33631104-978898A0-5880-45BA-8788-8CB3F2DB1F90Q33648339-616D109D-EF94-4A69-B35B-9D7228EBB225Q33739145-1F010A83-1E2B-46CA-B82F-337B12FF7EA0Q34047477-92CB0BF7-A1AB-4BD2-A12E-F2D3255A8508Q34048752-3ED12F07-1C82-4628-A8B9-A60A3967F0D5Q34064882-3889B38F-3E51-4EEF-8A5F-B1473077B659Q34481429-E779A09D-3E5E-4162-BEB7-970E71955248Q34586396-64A12634-A435-4276-AADE-23A217D805B4Q34766299-B1B76F45-204F-46EC-BE7E-75717E9C49BCQ35242585-E7E56EF7-5DB8-416A-AA81-F5D585C42B0EQ35646047-D044A78F-261F-4CF1-A327-9CD23B4D004FQ36288404-64A11A2B-4D22-485B-9990-AD9EB7B6AC14Q36290295-18F107E2-59B8-4B31-96EC-72792F9182CBQ36451941-95A03B1A-E2D8-434E-B558-42A031DC7209Q36506935-DF772CD7-150C-4ECA-9B7E-631ADA1B2007Q36559862-CC6F0579-17DB-43F2-8BB2-FC84EDD6AEEEQ36576382-ED773CE2-39F3-4CD9-A5F0-BDB8A9F6D966Q36811958-1C868CF6-73B5-468A-9569-16E1C868999BQ37144953-535F8FAD-AF10-42D3-872E-DC0697ED0801Q37417999-BCA4541C-419D-4AC6-AD99-E6C658DA6A4EQ37527686-05645502-8EAF-4DF4-B180-1B0D7C0EF14DQ37611819-456B6D03-08C3-4059-9169-30ACA99AA6C8Q37967737-22A33F2A-7B3B-4239-903F-3AE97F80F0B0Q38128299-1EF1ACD6-A168-46C8-A480-6DC40CC4A2A9Q38961608-0A36F411-2E0D-4A6F-A004-1500D9F4C02FQ39403799-90554E8C-875B-4050-9BBB-DA820B240C67Q39602767-A20B9152-82D7-4585-8A26-C7BB98E2D0D0Q40088796-0D814110-1C84-4580-919A-1269CFC5D539Q41780515-C7F748A1-35C1-4EF7-9AF7-26A3EAD38757Q45324462-5FC79478-945F-4768-A5DF-8C40DBC1D532
P2860
Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mapping a region of hepatitis ...... utralization escape mutations.
@ast
Mapping a region of hepatitis ...... utralization escape mutations.
@en
type
label
Mapping a region of hepatitis ...... utralization escape mutations.
@ast
Mapping a region of hepatitis ...... utralization escape mutations.
@en
prefLabel
Mapping a region of hepatitis ...... utralization escape mutations.
@ast
Mapping a region of hepatitis ...... utralization escape mutations.
@en
P2093
P2860
P356
P1433
P1476
Mapping a region of hepatitis ...... utralization escape mutations.
@en
P2093
Anasuya Saha
Jinming Xia
Patrick Lau
Steven K H Foung
Thomas Krey
Zhen-Yong Keck
P2860
P304
10451-10463
P356
10.1128/JVI.05259-11
P407
P50
P577
2011-08-03T00:00:00Z